The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | CAR T-cell therapy is feasible in patients 80 years of age or older with B-cell lymphoma
Julio Chavez, MD, MS, Moffitt Cancer Center, Tampa, FL, presents the results from a multicenter study looking at patients 80 and older who received approved CAR T-cell therapies for B-cell lymphomas. CAR T-cell therapy was effective and generally safe in these patients, with similar response rates to those observed in younger populations. The rates of cytokine release syndrome (CRS) and neurotoxicity were also comparable, although recovery following the occurrence of neurotoxicity was likely longer in these older patients. Dr Chavez emphasizes that age should not be a contraindication when considering a patient for CAR-T, as evidenced by these encouraging findings. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Genmab, Kite, Novartis, BMS, Allogene.
